Your browser doesn't support javascript.
loading
The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis.
Khanna, Dinesh; Berrocal, Veronica J; Giannini, Edward H; Seibold, James R; Merkel, Peter A; Mayes, Maureen D; Baron, Murray; Clements, Philip J; Steen, Virginia; Assassi, Shervin; Schiopu, Elena; Phillips, Kristine; Simms, Robert W; Allanore, Yannick; Denton, Christopher P; Distler, Oliver; Johnson, Sindhu R; Matucci-Cerinic, Marco; Pope, Janet E; Proudman, Susanna M; Siegel, Jeffrey; Wong, Weng Kee; Wells, Athol U; Furst, Daniel E.
Afiliação
  • Khanna D; University of Michigan, Ann Arbor.
  • Berrocal VJ; University of Michigan, Ann Arbor.
  • Giannini EH; Cincinnati Children's Hospital, Cincinnati, Ohio.
  • Seibold JR; Scleroderma Research Consultants, Litchfield, Connecticut.
  • Merkel PA; University of Pennsylvania, Philadelphia.
  • Mayes MD; University of Texas Health Science Center at Houston.
  • Baron M; Jewish General Hospital and McGill University, Montreal, Quebec, Canada.
  • Clements PJ; University of California, Los Angeles.
  • Steen V; Paris Descartes University and Cochin Hospital, AP-HP, Paris, France.
  • Assassi S; University of Texas Health Science Center at Houston.
  • Schiopu E; University of Michigan, Ann Arbor.
  • Phillips K; University of Michigan, Ann Arbor.
  • Simms RW; Boston University, Boston, Massachusetts.
  • Allanore Y; Paris Descartes University and Cochin Hospital, AP-HP, Paris, France.
  • Denton CP; Royal Free and University College London Medical School, London, UK.
  • Distler O; University Hospital Zurich, Zurich, Switzerland.
  • Johnson SR; Toronto Western Hospital and University of Toronto, Toronto, Ontario, Canada.
  • Matucci-Cerinic M; Azienda Ospedaliero-Universitaria Careggi (AOUC) and University of Florence, Florence, Italy.
  • Pope JE; Schulich School of Medicine, Western University, London Campus, and St. Joseph's Health Care, London, Ontario, Canada.
  • Proudman SM; Royal Adelaide Hospital and University of Adelaide, Adelaide, South Australia, Australia.
  • Siegel J; Genentech/Roche, San Francisco, California.
  • Wong WK; University of California, Los Angeles.
  • Wells AU; Royal Brompton Hospital, London, UK.
  • Furst DE; University of California, Los Angeles.
Arthritis Rheumatol ; 68(2): 299-311, 2016 Feb.
Article em En | MEDLINE | ID: mdl-26808827
ABSTRACT

OBJECTIVE:

Early diffuse cutaneous systemic sclerosis (dcSSc) is characterized by rapid changes in the skin and internal organs. The objective of this study was to develop a composite response index in dcSSc (CRISS) for use in randomized controlled trials (RCTs).

METHODS:

We developed 150 paper patient profiles with standardized clinical outcome elements (core set items) using patients with dcSSc. Forty scleroderma experts rated 20 patient profiles each and assessed whether each patient had improved or not improved over a period of 1 year. Using the profiles for which raters had reached a consensus on whether the patients were improved versus not improved (79% of the profiles examined), we fit logistic regression models in which the binary outcome referred to whether the patient was improved or not, and the changes in the core set items from baseline to followup were entered as covariates. We tested the final index in a previously completed RCT.

RESULTS:

Sixteen of 31 core items were included in the patient profiles after a consensus meeting and review of test characteristics of patient-level data. In the logistic regression model in which the included core set items were change over 1 year in the modified Rodnan skin thickness score, the forced vital capacity, the patient and physician global assessments, and the Health Assessment Questionnaire disability index, sensitivity was 0.982 (95% confidence interval 0.982-0.983) and specificity was 0.931 (95% confidence interval 0.930-0.932), and the model with these 5 items had the highest face validity. Subjects with a significant worsening of renal or cardiopulmonary involvement were classified as not improved, regardless of improvements in other core items. With use of the index, the effect of methotrexate could be differentiated from the effect of placebo in a 1-year RCT (P = 0.02).

CONCLUSION:

We have developed a CRISS that is appropriate for use as an outcome assessment in RCTs of early dcSSc.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Metotrexato / Avaliação de Resultados em Cuidados de Saúde / Antirreumáticos / Esclerodermia Difusa Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Metotrexato / Avaliação de Resultados em Cuidados de Saúde / Antirreumáticos / Esclerodermia Difusa Idioma: En Ano de publicação: 2016 Tipo de documento: Article